NCT06436612 Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)
| NCT ID | NCT06436612 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Jonsson Comprehensive Cancer Center |
| Condition | Abdominopelvic Sarcomas |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-05-30 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 20 participants in total. It began in 2024-05-30 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent advances in radiation treatment have allowed for higher doses per treatment to be delivered safely. This study plans to use an MRI-guided linear accelerator to deliver the radiation treatment to ensure that the radiation dose is administered to the cancerous tumor, not the vital body organs. Potential participants with a sarcoma diagnosis will be referred to Radiation Oncology during this study. If the participant is interested in participating in this study, s/he receives radiation treatment daily for 5 consecutive days except for weekends and holidays. Within 12 weeks of completing the radiation therapy, the participant will have the primary tumor surgically removed. The radiation oncology team will follow the patients for 5 years after completing radiation therapy.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed sarcoma * Primary or recurrent disease involving the abdomen or pelvis * Resectable primary lesion * Age ≥ 12 years old * Karnofsky performance status (KPS) ≥ 70 or Eastern Cooperative Oncology Group (ECOG) 0-2 * If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented Exclusion Criteria: * Active treatment of a separate malignancy * History of prior irradiation to the area targeted for treatment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06436612 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Abdominopelvic Sarcomas. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06436612 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06436612 currently recruiting?
Yes, NCT06436612 is actively recruiting participants. Contact the research team at cpalodichuk@mednet.ucla.edu for enrollment information.
Where is the NCT06436612 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06436612 clinical trial?
NCT06436612 is sponsored by Jonsson Comprehensive Cancer Center. The trial plans to enroll 20 participants.